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Objectives: Significant hypotension after carotid endarterectomy (CEA) and carotid angioplasty with stenting (CAS) has
been correlated with adverse outcomes. The objective of this study was to determine risk factors that predict hypotension
after patients undergo CEA and CAS.
Methods: The review included 1474 CEA patients and 157 CAS patients who underwent procedures from 2002 to 2008.
Specific patient characteristics, such as comorbid diseases, degree of carotid stenosis, presence of neurologic symptoms,
and preprocedure medications, were assessed. Also reviewed were specific postprocedural clinical outcomes, including
hypotension requiring pressors, myocardial infarction, stroke, death, and hospital length of stay.
Results: The incidence of clinically significant hypotension was 12.6% in CEA patients and 35% in CAS patients (P <
.001). Clinically significant hypotension was correlated with increased postprocedural myocardial infarction (2.1% vs
0.5%, P  .022), increased mortality (2.1% vs 0.1%, P < .001), and length of stay >2 days (46.3% vs 27.4%, P  .01).
Hypotension was not associated with increased postprocedural strokes (0.8% vs 0.6%, P  .75) or recurrent neurologic
symptoms (0.4% vs 0.3%, P  .55). Preoperative nitrate use predicted a greater incidence of postprocedural hypotension
(P  .043). A history of tobacco use was correlated with postprocedure hypotension (P  .033). Preprocedural strokes,
the use of calcium channel blockers, -blockers, angiotensin-converting enzyme inhibitors, prior myocardial infarction,
degree of preprocedural carotid stenosis, type of stent, previous ipsilateral and contralateral interventions, and female
gender did not correlate with postprocedural hypotension (P >.05).
Conclusions: Postprocedural hypotension occurs more commonly with CAS than CEA and is associated with increased
postprocedural myocardial infarction and length of stay, and death. Nitrates and tobacco use predict a higher incidence
of postprocedural hypotension. High-risk patients should be aggressively managed to prevent the increased morbidity
and mortality due to postprocedural hypotension. (J Vasc Surg 2009;50:526-33.)An estimated 750,000 cerebrovascular accidents (strokes)
occur annually, leading to200,000 fatalities.1 More than
two-thirds of stroke survivors are permanently disabled.2
Within the last decade, the gold standard of carotid endar-
terectomy (CEA) for the prevention of strokes in symptom-
atic3,4 and asymptomatic patients5,6 has been challenged
by the proliferation of carotid angioplasty with stenting
(CAS).7-10
A high incidence of hypotension observed after CAS
was noted in several large studies.7,11 Several reports have
shown a higher incidence of hypotension after CAS than
after CEA.12-17 Postprocedural hypotension in this partic-
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526ular patient population has been associated with an in-
creased incidence of complications, poor long-term prog-
nosis, and death.14,17 Many theorize that this complication
may occur in part due to excessive stretching of the barore-
ceptors in the carotid bulb by the angioplasty and stenting
procedures.13 Supporting this hypothesis is the observation
that the incidence of hypotension associated with balloon-
expanded stents is 34% vs 14% for self-expanding stents.16
Although some groups have advocated prophylactic
administration of atropine before surgery,14 or even tem-
porary transvenous pacemakers,15 no clinical trials have
been performed to date to evaluate the efficacy of these
modalities. In addition, few studies to date have definitively
identified the preoperative risk factors that predict for a
higher incidence of hypotension after the CEA or CAS
procedure.
The objective of this study was to determine which risk
factors predict hypotension in patients after CEA and CAS.
For this study, we retrospectively reviewed the medical
records of consecutive CEA and CAS patients from three
medical institutions. We analyzed these patients to deter-
mine the effect of postprocedural hypotension on clinical
outcomes. We also analyzed patient characteristics and
other aspects of these procedures to determine potential
risk factors that predict postprocedural hypotension.
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Institutional Review Board approval was obtained from
each participating institution for this study. All patients
who had undergone CEA or CAS in participating institu-
tions from May 2002 to June 2008 were included in this
study. The decision to perform CAS or CEA was made
according to patient preference and overall evaluation by
the vascular surgeon. There were a few relative exclusion
criteria for CEA, including prior neck radiotherapy and
high cervical lesions not accessible by CEA. The only
exclusion criterion for CAS was complete ipsilateral carotid
occlusion or completed, massive hemispheric stroke. This
study was not a randomized trial.
Significant postprocedural hypotension was defined as
40 mm Hg drop in systolic blood pressure or a systolic
blood pressure 90 mm Hg sustained for 1 hour after
carotid intervention, as has been previously described.12-21
In addition, this hypotension must have occurred 1 to 2
hours after CEA or CAS was performed. Hypotensive
episodes that occurred after this immediate postprocedural
period were not included in this analysis.
These patients required continuous intravenous vaso-
pressor support during their stay in the intensive care unit.
The triggers for treating hypotension in these patients were
the persistence of hypotension (according to the criteria
listed) for 1 hour or the presence of symptoms related to
hypotension, such as dizziness, shortness of breath, and
signs of orthostasis.
Treatment of hypotension after CEA or CAS consisted
of a routine protocol of 500 mL of intravenous fluid
boluses, followed by the addition of intravenous vasopres-
sor medications such as dopamine or vasopressin if the
hypotension was sustained. Intravenous pressor agents
were titrated to the minimum dose required to maintain a
systolic blood pressure 90 mm Hg.
The study included 1631 patients, consisting of 157
CAS and 1474 CEA procedures. We retrospectively ana-
lyzed data for four groups of patients: for CAS, 102 patients
without significant hypotension (nonhypotensive CAS)
and 55 patients with significant hypotension (hypotensive
CAS); for CEA, 1288 patients without significant hypoten-
sion (nonhypotensive CEA) and 186 patients with signifi-
cant hypotension (hypotensive CEA).
The anatomic criteria by which patients had been ac-
cepted for CAS were identical to the criteria used for CEA.
These were an internal carotid artery stenosis of 80%
stenosis (defined as a peak systolic duplex velocity of125
cm/s), and an end diastolic internal carotid velocity of
125 cm/s corresponding to 80% to 89% stenosis for
asymptomatic patients. For symptomatic patients, we used
a definition of 50% stenosis (defined as a peak systolic
duplex velocity 125 cm/s, and an end diastolic velocity
125 cm/s).
Carotid duplex ultrasound (DUS) imaging was per-
formed preoperatively and for surveillance in the noninva-
sive vascular laboratories of participating institutions. Ul-
trasound technicians experienced in carotid imaging(Intersocietal Commission for the Accreditation of Vascu-
lar Laboratories or American College of Radiology certi-
fied) performed these studies. Interpretation of the results
was performed by both a radiologist and vascular surgeon.
CAS had been performed according to a standard pro-
tocol. All patients were pretreated with acetylsalicylic acid
(81 mg per day, aspirin) and clopidogrel (75 mg per day,
Plavix; Sanofi-Aventis, Bridgewater, NJ) for 5 days before
the procedure. CAS was performed under conscious seda-
tion in the Special Procedures Section of the Radiology
Department. Carotid stenting was performed using Smart
Precise (Cordis Inc, Miami Lakes, Fla), Acculink (Guidant
Corp, Indianapolis, Ind), and Exact (Abbott Vascular Inc,
Abbott Park, Ill) stents. All procedures used the Filter Wire
(Boston Scientific Inc, Natick, Mass), Accunet (Guidant
Inc), or Emboshield (Abbott Vascular Inc) cerebral protec-
tion devices. After placement of the cerebral protection
device, most patients underwent predilatation of the ca-
rotid stenosis with a 3.5-mm balloon. All patients under-
went postdilatation after stent placement with a 5- to
5.5-mm balloon. All patients received 0.5 mg of atropine
before balloon angioplasty to minimize bradycardia and an
additional 0.5 mg of atropine before final stent dilatation.
After the procedure, patients were maintained on clo-
pidogrel for 8 to 12 weeks, with aspirin therapy indefinitely.
These procedures were performed exclusively by vascular
surgeons. Routine arch angiograms were not performed
because this may increase the risk of stroke.18
Magnetic resonance arteriography was obtained to ex-
amine the arch before the procedure unless the patients had
renal insufficiency. Under the latter circumstances, the
carotid DUS imaging remained the sole imaging modality.
CEA was performed in the operating room under pri-
marily general or local anesthesia. Shunts were placed in-
traoperatively to minimize cerebral ischemic time based on
the preference of the vascular surgeon. All CEAs were
closed using a Dacron (DuPont, Wilmington, DE) or a
bovine pericardium patch. Patients received heparin (100
U/kg) immediately before shunt placement. Prophylactic
atropine dosing was not performed during CEA in contrast
to CAS procedures. CEA patients continued aspirin ther-
apy indefinitely after surgery.
To determine the effect of possible risk factors on
clinically significant hypotension after carotid reconstruc-
tion, we retrospectively collected data on baseline patient
characteristics, clinical outcomes, and other potential risk
factors as described below. We assessed baseline character-
istics such as gender, average age, degree of ipsilateral
carotid stenosis, degree of contralateral carotid stenosis,
prior strokes, prior transient ischemic attacks (TIA), atrial
fibrillation, diabetes, previous myocardial infarction (MI),
coronary artery disease (CAD), prior coronary artery bypass
grafting (CABG), chronic obstructive pulmonary disease
(COPD), hypertension, and a history of tobacco use (either
recent intake of tobacco products or a history of tobacco
use) to determine if significant differences existed in our
four patient subgroups that represented potential con-
founding factors to influence our analyses.
hemic
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from the participating institutions in this study, velocity
data corresponding to 50% stenosis was given a grade of
class I stenosis, 50% to 79% stenosis was class II, 80% to 99%
was class III, and total occlusion was class IV. We then
assessed the incidence of postprocedural MI (confirmed by
electrocardiograms and cardiac enzymes), TIA, strokes
(neurologic deficits lasting longer 1 hour with changes
noted on CT scans or magnetic resonance imaging of the
brain), death, and average length of stay to determine the
effect that postprocedural hypotension had on these mea-
sures of general clinical outcomes.
Baseline patient characteristics and potentially modifi-
able risk factors, such as preoperative medications, general
vs local anesthesia, the use of prosthetic patch materials, the
use of carotid shunts, and the type of carotid stent device
were further analyzed to determine which risk factors pre-
dicted a greater incidence of postprocedural hypotension.
The data for CAS and CEA patients were analyzed and
compared using analysis of variance (ANOVA) for interval
data and a 2 test for proportions. Variables with a value of
P .05 were considered statistically different. The P values
from the ANOVA and 2 tests are reported in the data
tables. Variables that were statistically different between
treatment groups underwent further post hoc testing with a
Student-Newman-Keuls test for further analysis with sub-
divided contingency tables, as appropriate. The P values
from these post hoc tests are reported separately in the
Results.
Potential risk factors for hypotension underwent further
logistic regression univariate and subsequent multivariate
analysis to determine which factors independently predicted a
greater risk of significant postprocedural hypotension. Addi-
tional subanalyses were performed for clinical outcomes
comparing only CAS or CEA patients, and similarly for
Table I. Patient characteristics
Variable CAS cohort
No. (%) or mean Hypotensive Nonhypote
Total patients 55 102
Male gender 33 (60) 62 (61
Age, mean y 71.9 70.4
Pre-op stenosis, grade
Ipsilateral 2.74 2.69
Contralateral 1.87 1.92
Prior stroke 5 (9) 10 (10
Prior TIA 6 (11) 10 (10
Atrial fibrillation 1 (2) 7 (7)
Diabetes mellitus 12 (22) 37 (36
Prior MI 8 (15) 21 (21
CAD 29 (54) 46 (46
Prior CABG 17 (31) 19 (19
COPD 7 (13) 33 (33
Hypertension 50 (91) 92 (90
Tobacco use 29 (57) 63 (63
CABG,Coronary artery bypass grafting;CAD, coronary artery disease;CAS,
obstructive pulmonary disease; MI, myocardial infarction; TIA, transient iscpotential risk factors for hypotension. These analyses wereperformed using the t test or 2 tests where appropriate.
Data processing and statistical analyses were performed
using SAS 9.1 software (SAS Institute Inc, Cary, NC).
RESULTS
The preoperative patient characteristics in the 102 non-
hypotensive CAS patients, 55 hypotensive CAS patients,
1288 nonhypotensive CEA patients, and 186 hypotensive
CEA patients were generally similar. The mean age was
70.4 in the nonhypotensive CAS group, 71.9 in the hypo-
tensive CAS group, 71.4 in the nonhypotensive CEA
group, and 70.6 the hypotensive CEA group (P  1.0).
There was also a predominance of men in all subgroups.
The degree of ipsilateral internal carotid stenosis was quite
severe in all groups, with an average grade of 2.67 to 2.78
corresponding to 70% stenosis to complete occlusion.
There were 11 patients (20%) with prior neurologic
symptoms in the hypotensive CAS cohort, 20 symptomatic
patients (20%) in the nonhypotensive CAS cohort, 40
patients (21%) with neurologic symptoms in the hypoten-
sive CEA cohort, and 307 symptomatic patients (24%) in
the nonhypotensive CEA cohort. These neurologic symp-
toms were either previous TIAs or strokes. Most patients
were asymptomatic before CEA and CAS. The nonhypo-
tensive CAS cohort had more patients with comorbid
COPD compared with the other subgroups (P .001). In
addition, tobacco use was also more prevalent in the hypo-
tensive CEA groups compared with the other cohorts (P
.01). These patients were similar with regards to the other
patient characteristics listed in Table I.
Overall clinical postprocedural outcomes were excel-
lent for both CEA and CAS patients. For all CEA patients,
the incidence of MI infarction was 0.7%, the incidence of
strokes was 0.6%, and mortality was 0.5%. For all CAS
patients, the incidence of MI was 1.3%, the incidence of
CEA cohort
PHypotensive Nonhypotensive
186 1288
120 (65) 799 (62) 1.0
70.6 71.4 .51
2.67 2.78 .41
2.01 2.06 .54
15 (8) 129 (10) 1.0
25 (13) 178 (14) .94
9 (5) 86 (7) .35
47 (25) 394 (21) .15
32 (17) 223 (17) 1.0
81 (44) 600 (47) .84
48 (26) 362 (28) .18
30 (16) 199 (15) .001
165 (89) 1142 (89) .34
138 (74) 810 (63) .01
ary angioplasty and stenting;CEA, carotid endarterectomy;COPD, chronic
attack; NS, not significant.nsive
)
)
)
)
)
)
)
)
)
)
coronstrokes was 1.3%, and mortality was 0%.
S, len
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of patients. Overall, the incidence of clinically significant
hypotension was 12.6% in CEA patients and 35% in CAS
patients (P  .001). No CAS patients died. Two patients
(0.2%) died in the nonhypotensive CEA group, and five
(3%) in the hypotensive CEA group. Clinically significant
hypotension predicted greater mortality after CEA com-
pared with all other subgroups (P  .001).
Postprocedural MI occurred in 2% of hypotensive CEA
and 2% of hypotensive CAS patients compared with 0.5% of
nonhypotensive CEA and 1% of nonhypotensive CAS pa-
tients (P  .022). Length of stay was an average of 2.49
days in the hypotensive CEA group compared with 1.97 in
the nonhypotensive CEA group, 2.06 in the hypotensive
CAS group, and 1.9 in the nonhypotensive CAS group
(P .01). Postprocedural strokes and TIA were not signif-
icantly different, and these results are listed in Table II. A
subanalysis of clinical outcomes for CAS patients is pre-
sented in Table II,A. No significant differences were noted
for the variables assessed between hypotensive and nonhy-
potensive CAS patients. In addition, another subanalysis of
clinical outcomes demonstrated a significant increase in the
rate of postoperative myocardial infarctions, death, and
length of stay for hypotensive CEA patients compared with
nonhypotensive CEA patients (Table II, B).
This analysis of the potential risk factors for clinically
significant hypotension after CEA and CAS produced the
following results. All potential risk factors underwent uni-
variate analysis. Those factors that were potentially signifi-
cant then underwent multivariate analysis to determine
Table II. Clinical outcomes
Post-op outcome
CAS cohort
Hypotensive Nonhypotensiv
(n  55) (n  102)
MI, No. (%) 1 (2) 1 (1)
TIA, No. (%) 0 (0) 2 (2)
Stroke, No. (%) 1 (2) 1 (1)
Death 0 (0) 0 (0)
Average LOS, d 1.9 (1-11) 2.06 (1-22)
CAS, Coronary angioplasty and stenting; CEA, carotid endarterectomy; LO
Table II, A. Clinical outcomes after carotid angioplasty
and stentinga
Outcome
Hypotensive Nonhypotensive
P(n  55) (n 102)
MI, No. (%) 1 (2) 1 (1) .77
TIA, No. (%) 0 (0) 2 (2) .76
Stroke, No. (%) 1 (2) 1 (1) .77
Death, No. (%) 0 (0) 0 (0) .85
Average LOS, d 1.9 (1-11) 2.06 (1-22) .77
LOS, Length of stay; MI, myocardial infarction; TIA, transient ischemic
attack.
aClinical outcomes were analyzed by t test or 2 tests where appropriate.which were independently associated with a higher risk ofpostprocedural hypotension. Preprocedural nitrate use
(isosorbide mononitrate, nitroglycerin [oral and transder-
mal], and isosorbide dinitrate) was present in 8% of hypo-
tensive CAS patients and 7% of hypotensive CEA patients
compared with 2% of nonhypotensive CAS patients and 4%
of nonhypotensive CEA patients (P  .043). Tobacco use
also was more prevalent in CAS and CEA patients who
developed hypotension and was identified as an indepen-
dent risk factor for hypotension (P  .033).
Baseline patient characteristics such as age, gender,
degree of preoperative ipsilateral stenosis, preoperative
contralateral stenosis, atrial fibrillation, prior ipsilateral pro-
cedure, prior contralateral procedure, diabetes, prior MI,
coronary artery disease, prior CABG, COPD, and hyper-
tension were not independent risk factors for postproce-
dural hypotension (P  .05). Preoperative medications
such as statins (3-hydroxy-3-methyl-glutaryl-CoA reduc-
tase inhibitors), antiplatelet agents (aspirin and clopi-
dogrel), Coumadin (Bristol-Myers Squibb, Princeton, NJ),
calcium channel blockers, diuretics (hydrochlorothiazide
and furosemide), oral diabetic agents (metformin and gly-
buride), -blockers, and angiotensin-converting enzyme
(ACE) inhibitors were also not significantly associated with
postprocedural hypotension.
Specific procedural factors such as local vs general an-
esthesia, bulb block technique, patch angioplasty after
CEA, and placement of carotid shunts were not protective
or harmful in terms of significant hypotension. These data
are summarized in Table III. A separate analysis was per-
formed to determine if specific stent devices were more
CEA cohort
P
Hypotensive Nonhypotensive
(n  186) (n  1288)
4 (2) 6 (0.5) .022
1 (1) 2 (0.2) .1
1 (1) 8 (1) .9
5 (3) 2 (0.2) .001
2.49 (1-22) 1.97 (1-34) .01
gth of stay; MI, myocardial infarction; TIA, transient ischemic attack.
Table II, B. Clinical outcomes after carotid
endarterectomya
Post-op outcome
Hypotensive Nonhypotensive
P(n  186) (n  1288)
MI, No. (%) 4 (2) 6 (0.5) .03
TIA, No. (%) 1 (1) 2 (0.2) .83
Stroke, No. (%) 1 (1) 8 (1) .71
Death, No. (%) 5 (3) 2 (0.2) .001
Average LOS, d 2.49 (1-22) 1.97 (1-34) .017
LOS, Length of stay; MI, myocardial infarction; TIA, transient ischemic
attack.
aClinical outcomes were analyzed by t test or 2 test where appropriate.efrequently associated with hypotension after CAS. No cor-
d to b
dural
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incidence of hypotension (Table IV).
An additional analysis of potential risk factors for hypo-
tension comparing only hypotensive CAS patients with
nonhypotensive CAS patients was also performed (Table
III, A). Of note, COPD was more common in nonhypo-
tensive CAS patients (33%) than in hypotensive CAS pa-
tients (13%; P  .01). In contrast to the findings from our
combined analysis of all CEA and CAS patients, nitrate use
and tobacco use were not significantly different between
hypotensive CAS and nonhypotensive CAS patients. Simi-
larly, an additional analysis of potential risk factors for
hypotension comparing only hypotensive CEA with non-
hypotensive CEA patients (Table III, B) found that to-
bacco use was more common in hypotensive CEA patients
(P .003); however, nitrate use failed to reach significance
(P  .1).
Some interesting findings trending toward significance
indicated that use of calcium channel blockers and -blockers
Table III. Potential risk factorsa
Variable
CAS cohort
No. (%) or mean
Hypotensive Nonhypotens
(n  55) (n 102)
Age, y 71.9 70.4
Male gender 33 (60) 62 (61)
Pre-op stenosis
Ipsilateral 2.74 2.69
Contralateral 1.87 1.92
Symptomatic lesions 13 (25) 25 (25)
Atrial fibrillation 1 (2) 7 (7)
Prior procedure
Ipsilateral 10 (18) 23 (23)
Contralateral 12 (22) 24 (24)
Diabetes mellitus 12 (22) 37 (36)
Statins 46 (84) 74 (73)
Antiplatelet agents 50 (91) 90 (89)
Coumadin 5 (9) 11 (11)
Calcium channel blockers 21 (38) 36 (36)
Diuretics 21 (38) 42 (42)
Oral diabetic drugs 10 (18) 33 (33)
-Blockers 33 (60) 51 (50)
ACE inhibitors 22 (40) 44 (44)
Nitrates 4 (8) 2 (2)
Prior MI 8 (15) 21 (21)
Coronary artery disease 29 (54) 46 (46)
Prior CABG 17 (31) 19 (19)
COPD 7 (13) 33 (33)
Hypertension 50 (91) 92 (90)
Tobacco use 29 (57) 44 (43)
Anesthesia
Local 54 (98) 101 (99)
General 1 (2) 1 (1)
Bulb block NA NA
Patch Angioplasty NA NA
Shunt NA NA
ACE, Angiotensin converting enzyme inhibitors; CABG, coronary artery by
tomy; COPD, chronic obstructive pulmonary disease; MI, myocardial infarc
aAll potential risk factors underwent univariate analysis. Those factors foun
which factors were independently associated with a higher risk of postprocewas more common among nonhypotensive CEA patients.In contrast, use of Coumadin and ACE inhibitors was more
common among hypotensive CEA patients. These associa-
tions failed to meet significance, however, and further
details are presented in Table III, B.
DISCUSSION
This study reports a combined analysis of CEA and
CAS to determine risk factors for clinically significant post-
procedural hypotension. We determined that hypotension
was more common with CAS than CEA. Clinically signifi-
cant hypotension was also associated with a greater inci-
dence of postprocedural MI and an increased length of stay
andmortality rate. Preoperative use of nitrates and a history
of tobacco use were the only independent risk factors that
we identified for a greater incidence of hypotension.
Previous studies have attempted to identify some po-
tential risk factors that place patients undergoing CEA and
CAS at greater risk for clinically significant hypotension and
adverse clinical outcomes. A study by Qureshi et al19 in 51
CEA cohort
OR P
Hypotensive Nonhypotensive
(n 186) (n 1,288)
70.6 71.4 1.12 .87
120 (65) 799 (62) .98 .67
2.67 2.78 1.05 1.0
2.01 2.06 1.12 1.0
46 (25) 370 (29) 1.1 .22
9 (5) 86 (7) 1.08 .81
5 (3) 33 (3) 1.22 .12
17 (9) 147 (11) 1.27 1.0
47 (25) 394 (31) 1.15 .47
135 (73) 953 (75) 1.09 .81
148 (80) 1,037 (81) .76 .86
26 (14) 123 (10) 1.01 .13
40 (22) 366 (29) 1.36 .25
60 (33) 470 (37) .95 .32
40 (22) 338 (27) .91 .55
92 (50) 719 (57) .96 .29
86 (47) 502 (39) .87 .12
13 (7) 52 (4) 1.92 .043
32 (17) 223 (17) 1.28 .78
81 (44) 600 (47) 1.24 .82
48 (26) 362 (28) 1.31 .94
30 (16) 199 (15) 1.15 .64
165 (89) 1142 (89) 1.2 .94
138 (74) 810 (63) 2.17 .033
1 (1) 12 (1) 1.02 1.0
185 (99) 1272 (99) .95 1.0
7 (4) 34 (3) .84 .66
182 (98.4) 1,234 (96) .99 1.0
145 (80) 983 (76) 1.12 .78
rafting; CAS, coronary angioplasty and stenting; CEA, carotid endarterec-
transient ischemic attack; NS, not significant; OR, odds ratio.
e potentially significant then underwent multivariate analysis to determine
hypotension.ive
pass g
tion;patients undergoing CAS identified previous MI and age as
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dure. However, neither of these risk factors was signifi-
cantly correlated with hypotension in CEA or CAS patients
in our larger study.
Another study identified tobacco abuse, diabetes,
and -blocker use as protective against hypotension after
CAS.12 These results were inconsistent with our findings,
and that study did not include patients undergoing CEA.
In addition, it is difficult to reconcile the known adverse
effects on vasomotor tone and endothelial dysfunction,
which are inherent to patients with a history of tobacco
abuse and diabetes, with these findings. Prior MI, age80
years, and female gender were identified in another study20
as associated with increased hypotension after 143 CAS
procedures. That study also did not include CEA proce-
dures, and the authors also concluded that these episodes of
hypotension were not associated with adverse cardiac
events.
Finally, one of the few large studies to address hypo-
tension after CEA indicated no demographic or proce-
dural factors that predicted a greater incidence of hypo-
tension.21 That study also concluded that hypotension
after CEA was transient and not associated with adverse
clinical outcomes.
The findings of these studies are inconsistent with our
Table III, A. Potential risk factors—carotid angioplasty
and stentinga
Variable
Hypotensive
(n  55)
Nonhypotensive
(n  102) PNo. (%) or mean
Age, y 71.9 (42-91) 70.4 (46-92) .38
Male gender 33 (60) 62 (61) .94
Pre-op stenosis, grade
Ipsilateral 2.74 (2-4) 2.69 (2-4) .62
Contralateral 1.87 (1-4) 1.92 (1-4) .80
Symptomatic lesions 13 (25) 25 (25) .94
Atrial fibrillation 1 (2) 7 (7) .32
Prior procedure
Ipsilateral 10 (18) 23 (23) .66
Contralateral 12 (22) 24 (24) .97
Diabetes mellitus 12 (22) 37 (36) .09
Statins 46 (84) 74 (73) .17
Antiplatelet agents 50 (91) 90 (89) .81
Coumadin 5 (9) 11 (11) .95
Calcium channel blockers 21 (38) 36 (36) .85
Diuretics 21 (38) 42 (42) .85
Oral diabetic drugs 10 (18) 33 (33) .09
-Blockers 33 (60) 51 (50) .30
ACE inhibitors 22 (40) 44 (44) .83
Nitrates 4 (8) 2 (2) .22
Prior MI 8 (15) 21 (21) .47
Coronary artery disease 29 (54) 46 (46) .46
Prior CABG 17 (31) 19 (19) .12
COPD 7 (13) 33 (33) .01
Hypertension 50 (91) 92 (90) .89
Tobacco use 29 (57) 44 (43) .33
Anesthesia
Local 54 (98) 101 (99) .77
General 1 (2) 1 (1) .77results: We have determined that clinically significant hy-potension is correlated with adverse clinical outcomes after
CEA and CAS. We also have evidence that only preopera-
tive nitrate use and tobacco use indicate those at higher risk
for these complications. The other potential risk factors
identified by previous studies were not correlated with a
greater incidence of hypotension in our investigation.
This study has some advantages compared with other
previous attempts to identify potential risk factors for clin-
Table III, B. Potential risk factors—carotid
endarterectomya
Variable
Hypotensive
(n  186)
Nonhypotensive
(n  1288) PNo. (%) or mean
Age, y 70.6 (49-90) 71.4 (38-92) .27
Male gender 120 (65) 799 (62) .83
Pre-op stenosis
Ipsilateral 2.67 (2-4) 2.78 (2-4) .29
Contralateral 2.01 (1-4) 2.06 (1-4) .25
Symptomatic lesions 46 (25) 370 (29) .24
Atrial fibrillation 9 (5) 86 (7) .43
Prior procedure
Ipsilateral 5 (3) 33 (3) .88
Contralateral 17 (9) 147 (11) .43
Diabetes mellitus 47 (25) 394 (31) .16
Statins 135 (73) 953 (75) .28
Antiplatelet agents 148 (80) 1,037 (81) .84
Coumadin 26 (14) 123 (10) .08
Calcium channel blockers 40 (22) 366 (29) .06
Diuretics 60 (33) 470 (37) .18
Oral diabetic drugs 40 (22) 338 (27) .20
-Blockers 92 (50) 719 (57) .12
ACE inhibitors 86 (47) 502 (39) .07
Nitrates 13 (7) 52 (4) .10
Prior MI 32 (17) 223 (17) .95
Coronary artery disease 81 (44) 600 (47) .49
Prior CABG 48 (26) 362 (28) .57
COPD 30 (16) 199 (15) .93
Hypertension 165 (89) 1,142 (89) .92
Tobacco use 138 (74) 810 (63) .003
Anesthesia
Local 1 (1) 12 (1) .91
General 185 (99) 1,272 (99) .64
Bulb block 7 (4) 34 (3) .53
Patch angioplasty 182 (98.4) 1,234 (96) .26
Shunt 145 (80) 983 (76) .82
ACE, Angiotensin converting enzyme inhibitors; CABG, coronary artery
bypass grafting; COPD, chronic obstructive pulmonary disease; MI, myo-
cardial infarction; NS, not significant.
aAll potential risk factors underwent analysis by t test or 2 tests, where
appropriate.
Table IV. Stent type and hypotensiona
CAS patients No. Acculink
Smart
precise Exact
Hypotensive, No. (%) 55 28 (51) 11 (20) 16 (29)
Nonhypotensive, No. (%) 102 66 (64) 18 (18) 18 (18)
CAS, Carotid angioplasty and stenting.
aAssociation of stent type and hypotension (P  NS).ically significant hypotension after CEA and CAS. First, to
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this specific issue. Our study included 1631 patients who
underwent 157 CAS and 1474 CEA procedures. In addi-
tion, this study directly addressed hypotension for both
CEA and CAS patients together and allowed for a direct
comparison of the effect of sustained hypotension on clin-
ical outcomes after CEA and CAS. Potential risk factors for
hypotension were also evaluated and compared for both
types of carotid reconstructions.
This study has some inherent limitations. The first is
that these data were retrospectively collected. Many inher-
ent biases are prevalent in this type of study, regardless of
the careful analysis by the investigators. The ability to
standardize the compliance of patients with preoperative
medications or the management of significant comorbid
diseases is not possible with this type of study. However,
the potential risk factors that we analyzed were docu-
mented with good reliability and are generally not subject
to recall biases. In addition, this study evaluated a number
of potential risk factors for postprocedural hypotension for
patients undergoing CEA or CAS. Because CAS is being
performed with an increased frequency throughout this
country, this investigation may provide insights that pre-
vent adverse outcomes in a growing number of patients.
Another limitation is that we did not analyze the ana-
tomic characteristics of the carotid lesions, such as plaque
proximity to the carotid bifurcation, degree of calcification,
and length of lesion, that other investigators have indicated
may predict for higher incidences of hypotension.12,16,18
Although these characteristics might indicate which pa-
tients are at greater risk for postprocedural hypotension,
risk factors such as age and gender cannot be modified
before procedure. In addition, one of these previous studies
that identified anatomic risk factors for a greater risk of
hypotension found no effect on clinical outcomes such as
stroke orMI associated with episodes of hypotension.21We
chose to focus more of our investigation on risk factors that
can be modified before carotid reconstruction, including
preoperative medications, anesthesia type, and stent type.
We attempted to determine how modification of these risk
factors might affect the incidence of clinically significant
postprocedure hypotension.
Hypotension can be associated with an increased risk of
untoward cardiac events, especially in patients with prior
myocardial ischemia and in patients with carotid occlusive
disease. The increase rate of MI that we noted after CEA
and CAS may in be partly attributed to the effect of hypo-
tension on diseased myocardium. However, the increase in
the rate of MI was far less than what we would expect with
an incidence of hypotension in 12.6% of CEA and 35% of
CAS patients. These complications are interrelated, but the
direct effect of hypotension on myocardial ischemia could
not be fully assessed in this investigation.
The identification of predictors of clinically significant
hypotension after CEA and CAS seems to be an elusive
task. Previous investigators have failed to clearly identify
any specific patients at risk for these adverse outcomes after
CEA and CAS.21,22 In addition, other investigators haveshown that common prophylactic measures to prevent
hypotension, such as the intraprocedural administration of
intravenous atropine, are ineffective.22,23 A recent, small
trial comparing intravenous dopamine with oral midodrine
(an -1 adrenergic receptor agonist) in patients undergo-
ing CAS showed promising results in clinical outcomes and
costs associated with these admissions.24 However, that
was a very limited study of only 4 patients receiving mido-
drine, and its findings require further evaluation by larger,
prospective, randomized investigations.
The only finding that seems to have a widespread effect
on practice patterns is that balloon-expandable stents are
associated with a greater incidence of hypotension and
adverse outcomes compared with newer self-expanding
stents.17,25 Our study only identified the potentially mod-
ifiable factors of preoperative nitrate use and tobacco use.
However, the design of our study did not allow us to
determine what affect that modification of these risk factors
would have on subsequent rates of clinically significant
hypotension after CEA and CAS.
A limitation inherent to any retrospective study is the
inability to fully determine medication compliance and
timing of dosing before procedures. Similarly, the timing
and magnitude of tobacco use cannot be fully character-
ized. The clinically relevant findings of our study are that
prolonged hypotension occurs after both CEA and CAS,
although with greater frequency after endovascular treat-
ment. These hypotensive episodes are also related to in-
creased MI, death, and longer hospital admissions. How-
ever, it is not possible to ascertain whether the hypotension
itself, or the vasopressor medications and additional intra-
venous fluids used to manage these hemodynamic distur-
bances, are the cause for these adverse outcomes.
There are several theories about the cause of sustained
hypotension after CEA and CAS. The most commonly
cited mechanism involves stretch or distortion of the
baroreceptors in the carotid bulb that triggers the glosso-
pharyngeal nerve to send impulses to the caudal medulla.
This results in decreased sympathetic activity and vasomo-
tor tone.20,22,26 Other investigators have suggested that
CEA and CAS modify the distensibility of the carotid
arteries, thus altering the shear stress present within these
vessels. This may necessitate a reset mechanism that adjusts
how pressure gradients are detected by the carotid sinus.
Temporarily, this may translate into transient hypotension
or hypotension.22,26 A final possible mechanism involves a
potential feedback mechanism of the chronically ischemic
brain attempting to protect itself from a perceived overper-
fusion after CEA or CAS.21 To date, none of these theories
have been fully substantiated through basic science or
clinical studies.
CONCLUSIONS
This study has demonstrated that clinically significant
hypotension is a more common occurrence after CAS com-
pared with CEA. Our findings show that these episodes of
sustained hypotension are related to increased adverse clin-
ical outcomes, including increased rates of MI and death.
JOURNAL OF VASCULAR SURGERY
Volume 50, Number 3 Park et al 533An analysis of many potential risk factors for hypotension
found nitrate use and tobacco use were significantly corre-
lated with an increased risk for hypotension; however, no
definitive recommendations against the use of nitrates can
be made from our results. What is clear from this investiga-
tion is that sustained hypotension after CEA and CAS
remains a significant problem for all patients undergoing
these carotid reconstructions. Further efforts are mandated
to identify those patients at increased risk for hypotension
after CEA and CAS to prevent adverse clinical outcomes.
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